Treatment Response Monitoring

Monitoring response to latest generation of cancer treatments

NanoVerita™ (RUO) is the first system developed by Biological Dynamics. The system includes a benchtop analyzer and a growing portfolio of treatment response monitoring OncoState™ assays (RUO).

The assay measures concentration of cell-free DNA (cfDNA) >300bp in plasma of patients with advanced Non-Small Cell Lung cancer who are undergoing treatments with latest immuno-oncology regimens.  The test is performed on a fully automated proprietary platform, it requires a small sample size (< 0.2 mL) and the results are available in less than 1 hour.

 
 
 Figure 1. Timeline of a patient with stage IV Non-Small Cell Lung Cancer. The red portions indicate elevation in plasma cfDNA levels (as measured by OncoState™IO) and correlate with lack of treatment response.

Figure 1. Timeline of a patient with stage IV Non-Small Cell Lung Cancer. The red portions indicate elevation in plasma cfDNA levels (as measured by OncoState™IO) and correlate with lack of treatment response.

 

Why hmw cfDNA is important

The assay isolates and quantifies cell-free dsDNA directly from plasma of lung cancer patients undergoing systemic therapies. Studies have suggested that the change in concentration of the serially measured dsDNA correlates with treatment response in cancers.